RxDoctor Payments Data

Jateum Blackburn

Family · Cleveland, TNNPI 1265818983

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $107,859 of the $143,199 with a category attached, or 75.3%. AbbVie accounts for 84.1% of it on its own, with 59 other manufacturers making up the rest. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$143,199in general payments, 2019–2025

Across 1,572 payments — averaging $91.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$120K
  • Livanova USA, Inc.$2K
  • UCB, Inc.$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Biohaven Pharmaceutical Holding Company Ltd.$1K
  • EMD Serono, Inc.$1K
  • plus $15K from 54 others

What the payments were for

  • Consulting fees$1500%
  • Speaking & faculty fees$107,85975%
  • Travel & lodging$8,9086%
  • Food & beverage$26,15518%
  • Education$1280%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)481$120,498
Livanova USA, Inc.7$2,134
UCB, Inc.101$1,637
Biohaven Pharmaceuticals, Inc.94$1,347
Biohaven Pharmaceutical Holding Company Ltd.60$1,254
EMD Serono, Inc.44$1,220
Neurelis, Inc.47$1,090
Biogen55$1,040
AstraZeneca(2 entities)32$895
Teva Pharmaceuticals USA, Inc.43$876
Neurocrine Biosciences, Inc.47$827
Pfizer46$686
Acadia Pharmaceuticals Inc28$633
Lundbeck LLC32$630
Argenx US, Inc.40$613
Eisai Inc.31$610
Novartis33$604
Bristol Myers Squibb28$514
MDD US Operations, LLC9$487
Johnson & Johnson(2 entities)23$424
Lilly USA, LLC27$414
Kyowa Kirin, Inc.21$377
Sunovion Pharmaceuticals Inc.38$347
CSL Behring11$322
SK Life Science, Inc.14$283
Avanir Pharmaceuticals, Inc.16$219
Medtronic3$208
Amgen(2 entities)11$202
Upsher-smith Laboratories LLC8$190
Otsuka America Pharmaceutical, Inc.10$186
Amneal Pharmaceuticals LLC8$172
Catalyst Pharmaceuticals, Inc.7$159
Sumitomo Pharma America, Inc.17$157
E.r. Squibb & Sons, L.L.C.3$153
Banner Life Sciences, LLC9$146
Sanofi6$137
TG Therapeutics, Inc.6$134
Genentech USA, Inc.6$128
Corium, LLC9$124
Supernus Pharmaceuticals, Inc.7$112
Scilex Pharmaceuticals Inc.6$100
Jazz Pharmaceuticals Inc.4$92
Acorda Therapeutics, Inc6$90
Boston Scientific4$90
Axsome Therapeutics, Inc.4$87
Tanabe Pharma America, Inc.5$79
Amylyx Pharmaceuticals, Inc.3$75
Octapharma USA, Inc.3$61
Impel Pharmaceuticals Inc.3$50
Cycle Pharmaceuticals Inc2$41
Alnylam Pharmaceuticals Inc.2$40
Mallinckrodt Hospital Products Inc.2$36
Arbor Pharmaceuticals, Inc.2$28
Takeda Pharmaceuticals U.S.A., Inc.1$25
Merz Pharmaceuticals, LLC1$23
Sanofi-aventis U.S. LLC1$19
Impel Pharmaceuticals LLC1$17
Nevro Corp.1$16
Sandoz1$15
Vanda Pharmaceuticals Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$143,199 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$26,163
Medicare patients
143
Services billed
253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine21$111,071
Nurtec OdtRimegepant Sulfate44$90,788
QuliptaAtogepant66$86,736
UbrelvyUbrogepant39$61,775
BriviactBrivaracetam32$42,902
Emgality PenGalcanezumab-Gnlm47$40,856
ZavzpretZavegepant Hcl13$14,107
Ajovy AutoinjectorFremanezumab-Vfrm12$11,077
Carbidopa-LevodopaCarbidopa/Levodopa209$4,772
Primidone124$3,980
Memantine Hcl196$3,659
Lacosamide30$3,436
Gabapentin285$3,234
Levetiracetam81$2,415
Carbidopa-Levodopa ErCarbidopa/Levodopa50$2,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$120,498$148,510105 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$876$111,07121 claims
PfizerNurtec Odt, Zavzpret$686$104,89557 claims
UCB, Inc.Briviact$1,637$42,90232 claims
Upsher-smith Laboratories LLCTopiramate$190$34128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Cleveland

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →